Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UF researcher urges caution in reducing blood pressure in patients with diabetes, coronary disease

15.03.2010
For patients with diabetes and heart disease, less isn't always more — at least when it comes to blood pressure.

New data show an increased risk of heart attack, stroke or death for patients having blood pressure deemed too high — or too low, according to Rhonda Cooper-DeHoff, Pharm.D., an associate professor of pharmacy and medicine at UF. She reported her findings today (Sunday, March 14) at the American College of Cardiology's 59th annual scientific session in Atlanta.

She recommends raising the systolic bar above 120 for blood pressure in patients with diabetes and coronary artery disease, saying that levels between 130 and 140 appear to be the most healthful.

Based on hypertension treatment guidelines, health-care practitioners have assumed that with regard to blood pressure, "the lower, the better," Cooper-DeHoff said. But, The International Verapamil SR-Trandolapril study, known as INVEST, suggests that the range considered normal for healthy Americans may actually be risky for those with a combined diagnosis of diabetes and coronary artery disease.

"Our data suggest that in patients with both diabetes and coronary artery disease, there is a blood pressure threshold below which cardiovascular risk increases," Cooper-DeHoff said.

As many as two out of three adults with diabetes have high blood pressure. Normal blood pressure as defined by the American Heart Association is less than 120 systolic and less than 80 diastolic. Blood pressure greater than 140 is still associated with a nearly 50 percent increase in cardiovascular risk in patients with diabetes. But efforts to reduce systolic blood pressure to below 130 did not appear to offer any additional benefit to diabetics with coronary artery disease compared with reduction of systolic blood pressure to between 130 and less than 140.

Cooper-DeHoff's study reveals for the first time that this group of patients also had a similar increase in risk when their blood pressure was controlled to lower than 115 systolic — the range recommended as normal by the American Heart Association.

Stephan Brietzke, M.D., an endocrinologist who did not participate in the research, was intrigued by the findings, saying that they parallel recent studies looking at blood sugar control, which suggest a U-shaped curve with higher cardiovascular risks at both "too high" and "too low" extremes.

Brietzke, an associate professor of clinical medicine at the University of Missouri-Columbia since 2002, led a multidisciplinary team that developed Veterans Health Administration and Department of Defense collaborative guidelines for the treatment of type 2 diabetes. He sees this as an important study for doctors treating patients with diabetes and cardiovascular disease.

"Identifying thresholds of when to initiate treatment, and when to say 'good enough,' is extremely important not only to optimize patient outcomes, but also to help reduce unnecessary costs of care," Brietzke said.

The AHA reports that heart disease or stroke is the top cause of death for people with diabetes, affecting more than 60 percent of patients. High blood pressure, common in diabetes, doubles the risk of cardiovascular disease.

The INVEST study is the first to evaluate the effects of blood pressure-lowering in diabetic patients diagnosed with coronary artery disease. Researchers analyzed data collected from 6,400 patients from fall 1997 to spring 2003. The patients, who were 50 or older, were recruited from more than 850 sites in 14 countries. The researchers further consulted the national death index for U.S.-enrolled patients for an additional five years to compare death rates of patients based on their blood pressure category ranging from tightly controlled to non-controlled hypertension.

Abbott Laboratories provided funding for INVEST. Cooper-DeHoff also received support from a National Institutes of Health career development award.

Linda Homewood | EurekAlert!
Further information:
http://www.ufl.edu

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

New insights into the world of trypanosomes

23.08.2017 | Life Sciences

New Test for Rare Immunodeficiency

23.08.2017 | Life Sciences

Cholesterol-lowering drugs may fight infectious disease

22.08.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>